

1. [Indian pharma firms ready complex generics pipeline for next wave of US growth](#)

– Business Standard

Indian pharma companies who have been riding high on the generics wave in the US are now readying themselves for the next leg of the race. With an increase in competition in the generics space, analysts expect segment growth to fall to 1% per cent by 2020 from a 15% CAGR over 2010-2015. It's the kind of gloomy outlook that could move Indian pharma giants to ready a pipeline that comprises speciality generics and biosimilars to make the most of the next growth wave in the US market.

1. [Indian pharma firms ready complex generics pipeline for next wave of US growth](#) – Business Standard
2. [NDA government more eager to cap drug prices than UPA](#) – Business Standard
3. [Pharma sector can touch Rs 4 lakh crore by 2020: Ananth Kumar](#) – Economic Times
4. [Govt working on policy to raise bulk drugs output](#) – Economic Times
5. [National mission of US is to cure cancer. What is ours?](#) – Business Today
6. [Infosys co-founders to promote healthcare innovations](#) – The Hindu
7. [Over 200 drugs under development, top 50 with \\$30 billion potential: Cipla](#) – Economic Times
8. [Will online pharmacies work in India, and are they even legal?](#) – Mint

2. [NDA government more eager to cap drug prices than UPA](#)

– Business Standard

The new National List of Essential Medicines (NLEM), notified by the NDA government on December 25 last year, has added 106 drugs and removed 70. In contrast, the previous NLEM — prepared under the UPA government in 2011 — added just 43 drugs and removed 47. As drug pricing control policy is made according to NLEM, it is estimated that the pharma industry will take a hit of Rs 6,000 crore this year.

This is just one of the many steps which the new government has taken which shows that its eagerness to cap drug prices is way more than the previous government.

3. [Pharma sector can touch Rs 4 lakh crore by 2020: Ananth Kumar](#)

– Economic Times

Indian pharmaceutical sector can double in the next four years and touch Rs 4 lakh crore on the back of key policy initiatives of the government, Union Minister Ananth Kumar said today.

"The overall growth rate of GDP is above 7 per cent while pharma sector in the country is growing fast at 14 per cent, and we are targeting this sector to touch Rs 4 lakh crore mark by 2020. That's why we have taken various policy initiatives and will keep doing that," Fertiliser Minister Ananth Kumar said.

Also appeared in [Business Standard](#) and [First Post](#)

4. [Govt working on policy to raise bulk drugs output](#)

– Economic Times

The government is working on a policy to raise the domestic output of bulk drugs and bring down imports.

The Department of Pharmaceuticals (DoP) has moved a Cabinet note on bulk drugs based on the recommendations of Katoch committee, Fertiliser Minister Ananth Kumar said today. Bulk drugs are used as raw materials by the pharmaceutical industry.

Also appeared in [The Hindu](#)

5. [National mission of US is to cure cancer. What is ours?](#) – Business Today  
In his last "State of the Union address" on January 12, US President Barack Obama announced a new national effort to cure cancer. Some may see it as a bit of an exaggeration to equate it to John F Kennedy's "Man on the moon" address to Congress where he committed to putting man on the moon, but the common element of a nation to pick one agenda and put all resources behind it can hardly be missed. This is despite the fact that cancer cure is a tough problem and research in this space has been on for decades.

6. [Infosys co-founders to promote healthcare innovations](#) – The Hindu  
Axilor Ventures, a business incubator run by Infosys co-founders, has partnered Narayana Health and government's Centre for Cellular and Molecular Platforms to promote innovations in healthcare, Axilor Co-Founder D. Shibulal said.

Axilor, is creating a virtual platform that will enable entrepreneurs and startups to seek technical and business advice. It will also provide access to research and clinical resources and help entrepreneurs raise funds.

In its first initiative, Axilor's virtual platform has introduced a nationwide innovation challenge called 'Healiate 2016'. It is focused on finding innovative solutions for diabetes. "There is an ecosystem being formed for innovation in the country. We want to bring focus on healthcare in a much more structured manner," Axilor Co-Founder D. Shibulal said.

7. [Over 200 drugs under development, top 50 with \\$30 billion potential: Cipla](#) – Economic Times  
Charting out its next phase of growth, homegrown drug major CiplaBSE -0.48 % is banking on over 200 drugs under development out of which "top 50 projects have potential of over \$30 billion".  
The Mumbai-based firm is also aiming to grow share of its North America business to overall sales to up to 25 per cent by 2020 on the back of intensified focus on R&D and filing for more approvals of generic drugs in the US. In a investor presentation, the company said it has strong product development and filing capabilities with "market leading respiratory and HIV portfolio with continuous R&D underway".

Also appeared in [DNA](#), [Financial Chronicle](#)

8. [Will online pharmacies work in India, and are they even legal?](#) – Mint  
It's a \$18 billion market set to grow to \$55 billion by 2020 and it's finally beginning to get the kind of attention from investors and entrepreneurs those numbers warrant—despite uncertainty over the legality of the business itself.

The business is online pharmacies, and according to start-up data tracker Tracxn, so far, the sector has attracted \$92.6 million funding with over \$70 million coming only in 2015.